USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: APHIOS CORPORATION
Address: 3 E GILL ST
WOBURN, MA 01801-1720
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,059,270.00 31
SBIR Phase II $4,168,529.00 5
STTR Phase I $258,398.00 1

Award List:

Improved Isolation of Marine Natural Products

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $75,000.00
Abstract:
The overall goal of this R&D program is to develop improved methodologies and manufacturingprocesses for the isolation of marine natural products with anticancer or anti-HIV activity. Thetherapeutic potential of marine natural products has rapidly advanced in recent years. One suchpotential… More

Fluorophore Labeled Nucleic Acid Probes

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Salifu Dakubu
Award Amount: $75,000.00
Abstract:
This investigation is aimed at devising ways and special instrumentation for using fluorescentlanthanide chelates, detected by time resolved fluorometry, as a means for detecting nucleic acids in avariety of settings such as Southern blots and cells or tissues (e.g., as in situ hybridization).… More

REVERSED MICELLAR FRACTIONATION

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: NSF
Principal Investigator: Maury Cosman
Award Amount: $65,000.00

Supercritical Fluid Extraction of Michellamine B

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $61,006.00

REVERSED MICELLAR FRACTIONATION

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: NSF
Principal Investigator: Maury Cosman
Award Amount: $271,353.00
Abstract:
Numerous compounds showing antineoplastic activity have been identified in the organic solvent extracts of plant material, microorganisms, and marine organisms. further investigation into the utility of these compounds as chemotherapeutic and anti-hiv agents has been hampered by their low natural… More

Supercritical Fluid Extraction of Michellamine B

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $637,570.00
Abstract:
Michellamine B is a potential anti-HIV agent isolated from the leaves of a Cameroonian vine,Ancistrocladus korupensis, which grows in the Korup region of Cameroon. Preclinical testing ofMichellamine B by the National Cancer Institute may be adversely impacted by raw materials availability,and the… More

Recovery of Pyrotechnic Ingredients Using Supercritical Fluids

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Dr. Glenn T. Hong
Award Amount: $68,166.00
Abstract:
Many pyrotechnics contain valuable resources which could be used in commercial applications, for example metals (e.g. magnesium, aluminum); metallic salts of copper, strontium, and barium; oxidizer (e.g. sodium nitrate, potassium Perchlorate); binders such as viton, and dyes which have reclaimed… More

Reversed Micellar Fractionation of...

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: NSF
Principal Investigator: Trevor Castor , Principal Investigator
Award Amount: $100,000.00

DEVELOPMENT OF A VIRUS FREE FIBRIN GLUE

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,400.00

TOPICAL TREATMENT OF KAPOSIS SARCOMA

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Castor, trevor p
Award Amount: $100,000.00

NOVEL ANTIHIV CHEMOTYPES FROM MARINE MICROORGANISMS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chikarmane, hemant
Award Amount: $100,000.00

SBIR Phase I: Supercritical Fluid Viral Inactivation in a Varying Potential Electrical Field

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: NSF
Principal Investigator: Trevor Castor
Award Amount: $75,000.00

NOVEL BIOADHESIVE MICROSPHERES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hong, Glenn T
Award Amount: $83,595.00

CRYSTALLIZATION OF THERAPEUTIC MATERIALS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hong, Glenn T
Award Amount: $100,000.00

DEVELOPMENT OF AN HIV THERAPEUTIC VACCINE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Castor, Trevor P
Award Amount: $100,000.00

SOLVENT FREE PROTEIN COMMINUTION

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $100,000.00
Abstract:
Not Available Technical Abstract (Limit your abstract to 200 words with no classified or proprietary information/data.) MSSI proposes the use of ultra wideband (UWB), nanosecond duration pulses for a fusing sensor waveform to determine the ordinance to target range with an accuracy of better than… More

SUPERFLUIDS--ELECTRIC FIELD VIRUS INACTIVATION

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $99,998.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $297,560.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $149,367.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $150,000.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $244,920.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $100,000.00

SUPERFLUIDS ISOLATION OF NATURAL ANTI-CANCER DRUGS

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $750,000.00

SUPERFLUIDS ISOLATION OF NATURAL ANTI-CANCER DRUGS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $0.00

DEVELOPMENT OF A NATURAL CANNABINOID PRODUCT

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $234,783.00
Abstract:
DESCRIPTION (provided by applicant): Marijuana (Cannabis sativa) and a number of cannabinoids including its primary psychoactive component, delta9-THC (delta9-tetrahydrocannabinol), show promise for treating pain and cachexia in cancer and AIDS patients. The overall goal of this research program is… More

Anti-Smallpox Therapeutics from Marine Micoorganisms

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $264,705.00
Abstract:
DESCRIPTION (provided by investigator): The terrorist events of September 11th and the recent criminal anthrax exposures have increased awareness of the use of smallpox as a biological weapon. A shortage of the vaccine and the incidence of vaccine-related deaths will preclude protection of everyone… More

Development of Novel Anti-Influenza Agents

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa A. Lallos
Award Amount: $305,212.00
Abstract:
DESCRIPTION (provided by applicant): Influenza is a common and serious respiratory illness affecting tens of thousands each year and causing 20,000 - 40,000 deaths. This significantly contributes to the loss of manpower hours and revenue each year. Annual vaccine programs are in place to protect… More

Development of Novel Anti-HIV Therapeutics

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa A. Lallos
Award Amount: $898,408.00
Abstract:
DESCRIPTION (provided by applicant): Currently, there are 42 million AIDS cases worldwide, with a majority present in the third world; 3.1 million deaths can be attributed to HIV and AIDS in 2002 alone. There is no vaccine against HIV, and AIDS, if untreated, will lead to the death of over 95% of… More

BIODEGRADABLE POLYMER ENCAPSULATED NANOPARTICLES FOR ORA

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor
Award Amount: $99,986.00

Alkylating Vitamin D Derivative

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: BOSTON UNIVERSITY
Principal Investigator: Trevor P. Castor
Award Amount: $258,398.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Prostate cancer is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US. There are currently no approved therapies for hormone-refractory prostate cancer. Epidemiological studies have demonstrated a strong… More

D9-THC for Marijuana Addiction

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $109,761.00
Abstract:
DESCRIPTION (provided by applicant): ?9-tetrahydrocannabinol (?9-THC) has been shown to alleviate marijuana withdrawal symptoms and thus has potential for treating cannabinoid dependence. However, the bioavailability of ?9-THC administered orally is poor a nd variable. In addition, it also requires… More

402 - RFP: N43-CM-87007-68 TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUEST

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $149,558.00
Abstract:
The aim of this project is the development of Tyrosyl DNA phosphodiesterase (Tdp1) inhibitors in order to enhance the activity of DNA topoisomerase I inhibitors.

CFI Inactivation of Human Plasma

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $344,267.00
Abstract:
DESCRIPTION (provided by applicant): The worldwide AIDS epidemic, the periodic emergence of Ebola and SARS, and the recent outbreaks of potentially pandemic strains of influenza such as H5N1 have highlighted a persistent concern in the health- care communi ty -- the need for effective sterilization… More

Alzheimer's Disease Therapeutic

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor P. Castor
Award Amount: $263,690.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack of a cure for AD will result in a demand for better and s afer AD drugs. All of the drugs on the… More

Alzheimer's Disease Therapeutic

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Trevor P. Castor – 781-932-6933
Award Amount: $2,409,606.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack of a cure for AD will result in a demand for better and safer AD drugs. All of the drugs on the… More

TAS:: 75 0896::TAS SBIR PHASE I TOPIC NCCAM 002

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor – 781-932-6933
Award Amount: $94,448.00
Abstract:
This Phase I, SBIR contract is to conduct a thorough biological and phytochemical analysis of Harpagophytum procumbens. This should result in discovery of new biologically active molecules and/or a more comprehensive understanding of the contributions madeby the known constituents.

SBIR PHASE 1 TOPIC 43

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trevor Castor – 781-932-6933
Award Amount: $149,440.00
Abstract:
The contractor will identify methodologies for broad spectrum inactivation of pathogens in red blood cell concentrates(RBCC). RBCCs are the main components of blood used in transfusion medicine, yet currently there are no FDAapproved methods for broad spectrum pathogen inactivation for RBCCs;… More